EZH2抑制剂GSK126对Neuro-2a细胞增殖分化的影响及其可能机制
发布时间：2019-07-26 05:30
【摘要】：正神经母细胞瘤(neuroblastoma,NB)是常见的儿童恶性肿瘤,在手术、放化疗及介入等多种手段综合治疗下,总体疗效仍然极差。近年来研究发现,果蝇zeste基因增强子同源物2(enhancer of zeste homolog 2,EZH2)能抑制相关抑癌基因,明显增加神经母细胞瘤发生、发展的风险~([1])。GSK126是一种新型的选择性EZH2抑制剂~([2-3]),其在实体瘤方面的药效探究目前相对较少。本文将对GSK126在神经母细胞瘤
[Abstract]:Positive neuroblastoma (neuroblastoma,NB) is a common malignant tumor in children. Under the combined treatment of surgery, radiotherapy, chemotherapy and intervention, the overall curative effect is still very poor. In recent years, it has been found that zeste gene enhancer 2 (enhancer of zeste homolog 2, EZH2) can inhibit related tumor suppressor genes and significantly increase the risk of neuroblastomas ([1]). GSK126 is a new selective EZH2 inhibitor ([2 鈮，
本文编号：2519362
[Abstract]:Positive neuroblastoma (neuroblastoma,NB) is a common malignant tumor in children. Under the combined treatment of surgery, radiotherapy, chemotherapy and intervention, the overall curative effect is still very poor. In recent years, it has been found that zeste gene enhancer 2 (enhancer of zeste homolog 2, EZH2) can inhibit related tumor suppressor genes and significantly increase the risk of neuroblastomas ([1]). GSK126 is a new selective EZH2 inhibitor ([2 鈮，
本文编号：2519362
本文链接：https://www.wllwen.com/yixuelunwen/yiyaoxuelunwen/2519362.html
最近更新
教材专著
